US Biopharmaceuticals Market

ID: MRFR/MED/49630-HCR
200 Pages
Nidhi Mandole
Last Updated: April 30, 2026
US Biopharmaceuticals Market Research Report By Product Type (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cellular Therapies), By Application (Oncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases), By End-use (Hospitals, Biotechnology Companies, Pharmaceutical Companies), and By Route of Administration (Intravenous, Subcutaneous, Intramuscular) - Growth & Industry Forecast 2025 To 2035
US Biopharmaceuticals Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.21%
2024 Market Size$ 92.1 Billion
2025 Market Size$ 95.98 Billion
2035 Market Size$ 145 Billion
Key Players
Companies such AbbVie
Amgen
Bristol-Myers Squibb
Gilead Sciences
Johnson & Johnson
Merck & Co.
Trends
  • Personalized Medicine
  • Sustainability Initiatives
  • Regulatory Adaptations
Opportunities
  • Enhanced Regulatory Frameworks
  • Rising Prevalence of Chronic Diseases
  • Investment in Research and Development
Summary Table of Contents Segmentation Download PDF
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Pharmaceutical, BY Product Type (USD Billion) | |
      1. 4.1.1 Monoclonal Antibodies | |
      2. 4.1.2 Recombinant Proteins | |
      3. 4.1.3 Vaccines | |
      4. 4.1.4 Cellular Therapies |
    2. 4.2 Pharmaceutical, BY Application (USD Billion) | |
      1. 4.2.1 Oncology | |
      2. 4.2.2 Autoimmune Diseases | |
      3. 4.2.3 Infectious Diseases | |
      4. 4.2.4 Cardiovascular Diseases |
    3. 4.3 Pharmaceutical, BY End-use (USD Billion) | |
      1. 4.3.1 Hospitals | |
      2. 4.3.2 Biotechnology Companies | |
      3. 4.3.3 Pharmaceutical Companies |
    4. 4.4 Pharmaceutical, BY Route of Administration (USD Billion) | |
      1. 4.4.1 Intravenous | |
      2. 4.4.2 Subcutaneous | |
      3. 4.4.3 Intramuscular 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 AbbVie (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Amgen (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Bristol-Myers Squibb (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Gilead Sciences (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Johnson & Johnson (US) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Merck & Co. (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Novartis (CH) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Roche (CH) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Sanofi (FR) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies | |
      10. 5.2.10 Takeda Pharmaceutical (JP) | | |
        1. 5.2.10.1 Financial Overview | | |
        2. 5.2.10.2 Products Offered | | |
        3. 5.2.10.3 Key Developments | | |
        4. 5.2.10.4 SWOT Analysis | | |
        5. 5.2.10.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 US MARKET ANALYSIS BY PRODUCT TYPE |
    6. 6.3 US MARKET ANALYSIS BY APPLICATION |
    7. 6.4 US MARKET ANALYSIS BY END-USE |
    8. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    9. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL |
    10. 6.7 RESEARCH PROCESS OF MRFR |
    11. 6.8 DRO ANALYSIS OF PHARMACEUTICAL |
    12. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL |
    13. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL |
    14. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL |
    15. 6.12 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 (% SHARE) |
    16. 6.13 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 TO 2035 (USD Billion) |
    17. 6.14 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE) |
    18. 6.15 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Billion) |
    19. 6.16 PHARMACEUTICAL, BY END-USE, 2024 (% SHARE) |
    20. 6.17 PHARMACEUTICAL, BY END-USE, 2024 TO 2035 (USD Billion) |
    21. 6.18 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
    22. 6.19 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
    23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    24. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    25. 7.2 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY PRODUCT TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY END-USE, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) |
    26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.3.1 |
    27. 7.4 ACQUISITION/PARTNERSHIP | |

US Biopharmaceuticals Market Segmentation

US Biopharmaceuticals Market By Product Type (USD Billion, 2025-2035)

  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Cellular Therapies

US Biopharmaceuticals Market By Application (USD Billion, 2025-2035)

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Cardiovascular Diseases

US Biopharmaceuticals Market By End-use (USD Billion, 2025-2035)

  • Hospitals
  • Biotechnology Companies
  • US Biopharmaceuticals Market Companies

US Biopharmaceuticals Market By Route of Administration (USD Billion, 2025-2035)

  • Intravenous
  • Subcutaneous
  • Intramuscular

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.